Skip to main content

Mahoney Michael F's Form 4 filing

Boston Scientific Corp (BSX) · filed Oct 8, 2024

Accession no.
0001225208-24-009234
Filed
Oct 8, 2024
Trade date
Oct 7, 2024
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $13.8M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahoney Michael FCIK 0001533022Director, Officer (Chairman, President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 7, 2024Common StockMOption exerciseAcquired+56,211$17.26+$970,201.861,679,198Direct
Oct 7, 2024Common StockMOption exerciseAcquired+55,675$16.31+$908,059.251,734,873Direct
Oct 7, 2024Common StockSSaleDisposed−80,692$84.31F2−$6,803,142.521,654,181Direct
Oct 7, 2024Common StockSSaleDisposed−82,085$84.94F3−$6,972,299.91,572,096Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 7, 2024Common StockMOption exerciseDisposed−56,211$0.00$0224,846Direct
Oct 7, 2024Common StockMOption exerciseDisposed−55,675$0.00$055,676Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.73, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $84.75 to $85.24, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)